Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
SPECTRUM: early clinical experience from the first global real-world study of aflibercept 8 mg in patients with neovascular age-related macular degeneration.
Bailey C, Lange C, Chaudhary V, Lanzetta P, Oubraham H, Kirchner M, Machewitz T, Allmeier H, Zhang X, Hasanbasic Z, Munk MR; SPECTRUM study investigators. Bailey C, et al. Among authors: hasanbasic z. Eye (Lond). 2026 Jan 30. doi: 10.1038/s41433-026-04260-3. Online ahead of print. Eye (Lond). 2026. PMID: 41617984 No abstract available.
Infographic: SPECTRUM: study design of the global real-world study of aflibercept 8 mg in the treatment of neovascular age-related macular degeneration and diabetic macular edema.
Bailey C, Lange C, Munk MR, Lanzetta P, Oubraham H, Machewitz T, Allmeier H, Zhang X, Morgan-Warren P, Hasanbasic Z, Chaudhary V; SPECTRUM study investigators. Bailey C, et al. Among authors: hasanbasic z. Eye (Lond). 2026 Jan 16. doi: 10.1038/s41433-025-04140-2. Online ahead of print. Eye (Lond). 2026. PMID: 41545711 No abstract available.
Intravitreal aflibercept 8 mg versus 2 mg in Asian patients with neovascular age-related macular degeneration: 48-week analysis of the Phase 3 PULSAR trial.
Chang A, Sun X, Iida T, Lai TYY, Wong TY, Cheung CMG, Lee WK, Zhang X, Schulze A, Schmidt-Ott UM, Zhao M, Hasanbasic Z, Leal S, Chen SJ; PULSAR study investigators. Chang A, et al. Among authors: hasanbasic z. Asia Pac J Ophthalmol (Phila). 2026 Jan-Feb;15(1):100278. doi: 10.1016/j.apjo.2026.100278. Epub 2026 Jan 8. Asia Pac J Ophthalmol (Phila). 2026. PMID: 41519383 Free article. Clinical Trial.
Intravitreal Aflibercept 8 mg for Diabetic Macular Edema: Ninety-Six-Week Results from the Randomized Phase 2/3 PHOTON Trial.
Do DV, Wykoff CC, Sivaprasad S, Brown DM, Boyer DS, Sakamoto T, Win P, Joshi S, Salehi-Had H, Seres A, Berliner AJ, Leal S, Vitti R, Chu KW, Reed K, Cheng Y, Bhore R, Bai Z, Schmidt-Ott U, Schmelter T, Schulze A, Hasanbasic Z, Morgan-Warren PJ, Zhang X, Hirshberg B, Yancopoulos GD; PHOTON Investigators. Do DV, et al. Among authors: hasanbasic z. Ophthalmology. 2025 Nov 10:S0161-6420(25)00707-9. doi: 10.1016/j.ophtha.2025.10.028. Online ahead of print. Ophthalmology. 2025. PMID: 41223900 Free article.
Intravitreal Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration: Ninety-Six-Week Results from the Randomized Phase 3 PULSAR Trial.
Korobelnik JF, Lanzetta P, Leal S, Holz FG, Clark WL, Eichenbaum D, Iida T, Sun X, Berliner AJ, Schulze A, Zhao M, Schmelter T, Schmidt-Ott U, Zhang X, Morgan-Warren P, Hasanbasic Z, Vitti R, Chu KW, Reed K, Bhore R, Cheng Y, Bai Z, Hirshberg B, Yancopoulos GD, Wong TY; PULSAR Investigators. Korobelnik JF, et al. Among authors: hasanbasic z. Ophthalmology. 2026 Jan;133(1):39-50. doi: 10.1016/j.ophtha.2025.08.022. Epub 2025 Aug 26. Ophthalmology. 2026. PMID: 40876598 Free article. Clinical Trial.
Sustained disease control with aflibercept 8 mg: a new benchmark in the management of retinal neovascular diseases.
Korobelnik JF, Lanzetta P, Wykoff CC, Wong TY, Zhang X, Morgan-Warren P, Fitzpatrick S, Leal S, Brunck L, Hasanbasic Z, Chu KW, Reed K, Sivaprasad S. Korobelnik JF, et al. Among authors: hasanbasic z. Eye (Lond). 2024 Dec;38(17):3218-3221. doi: 10.1038/s41433-024-03312-w. Epub 2024 Aug 31. Eye (Lond). 2024. PMID: 39217260 Free PMC article. No abstract available.
PERSEUS 24-month analysis: a prospective non-interventional study to assess the effectiveness of intravitreal aflibercept in routine clinical practice in Germany in patients with neovascular age-related macular degeneration.
Eter N, Hasanbasic Z, Keramas G, Rech C, Sachs H, Schilling H, Wachtlin J, Wiedemann P, Framme C; PERSEUS Study Group. Eter N, et al. Among authors: hasanbasic z. Graefes Arch Clin Exp Ophthalmol. 2021 Aug;259(8):2213-2223. doi: 10.1007/s00417-021-05073-8. Epub 2021 Feb 6. Graefes Arch Clin Exp Ophthalmol. 2021. PMID: 33547967 Free PMC article.
Importance of continuous treatment with intravitreal aflibercept injections in patients with neovascular age-related macular degeneration-12-month post hoc analysis of the PERSEUS real-world evidence study.
Wachtlin J, Eter N, Hasanbasic Z, Keramas G, Rech C, Sachs H, Schilling H, Wiedemann P, Framme C. Wachtlin J, et al. Among authors: hasanbasic z. Graefes Arch Clin Exp Ophthalmol. 2021 Mar;259(3):601-611. doi: 10.1007/s00417-020-04803-8. Epub 2020 Aug 13. Graefes Arch Clin Exp Ophthalmol. 2021. PMID: 32789651 Free PMC article.
15 results